Carfilzomib And Pomalidomide Pass Phase II
This article was originally published in The Pink Sheet Daily
Executive Summary
Proteolix’s novel proteasome inhibitor set for larger trial of relapsed, refractory myeloma.
You may also be interested in...
Carfilzomib Multiple Myeloma Data Do New Onyx Parent Proud At ASH '09
When all else fails, call on carfilzomib: Phase II data support end-2010 NDA filing for next-generation Velcade.
Carfilzomib Multiple Myeloma Data Do New Onyx Parent Proud At ASH '09
When all else fails, call on carfilzomib: Phase II data support end-2010 NDA filing for next-generation Velcade.
Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later
Takeda announced June 27 that U.S. FDA had denied approval of its type 2 diabetes agent alogliptin, a potential blockbuster poised to compete with similar molecules from Merck and the team of Bristol-Myers Squibb and AstraZeneca. The setback will delay alogliptin's launch by at least three years - and possibly longer - depending on the additional studies required by regulators